- Home
- RGC vs HSIC Comparison
RGC vs HSIC Comparison
Compare RGC & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- HSIC
- Stock Information
- Founded
- RGC 2014
- HSIC 1932
- Country
- RGC Hong Kong
- HSIC United States
- Employees
- RGC N/A
- HSIC N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- HSIC Medical Specialities
- Sector
- RGC Health Care
- HSIC Health Care
- Exchange
- RGC Nasdaq
- HSIC Nasdaq
- Market Cap
- RGC 8.4B
- HSIC 7.7B
- IPO Year
- RGC 2021
- HSIC 1995
- Fundamental
- Price
- RGC $14.18
- HSIC $64.76
- Analyst Decision
- RGC
- HSIC Buy
- Analyst Count
- RGC 0
- HSIC 12
- Target Price
- RGC N/A
- HSIC $76.25
- AVG Volume (30 Days)
- RGC 197.4K
- HSIC 1.5M
- Earning Date
- RGC 10-24-2025
- HSIC 11-04-2025
- Dividend Yield
- RGC N/A
- HSIC N/A
- EPS Growth
- RGC N/A
- HSIC 15.03
- EPS
- RGC N/A
- HSIC 3.11
- Revenue
- RGC N/A
- HSIC $12,773,000,000.00
- Revenue This Year
- RGC N/A
- HSIC $4.61
- Revenue Next Year
- RGC N/A
- HSIC $3.50
- P/E Ratio
- RGC N/A
- HSIC $20.78
- Revenue Growth
- RGC N/A
- HSIC 2.29
- 52 Week Low
- RGC $0.09
- HSIC $60.56
- 52 Week High
- RGC $83.60
- HSIC $82.49
- Technical
- Relative Strength Index (RSI)
- RGC 38.52
- HSIC 52.27
- Support Level
- RGC $15.79
- HSIC $62.15
- Resistance Level
- RGC $17.45
- HSIC $64.33
- Average True Range (ATR)
- RGC 1.25
- HSIC 1.23
- MACD
- RGC -0.16
- HSIC 0.22
- Stochastic Oscillator
- RGC 6.91
- HSIC 95.88
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.